Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), drawn from the whole corpus: 2 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Median survival remains under a year for most patients.
Only a third have an actionable alteration and the gain from targeting it is modest.
Patients too unwell for CUPISCO-style induction have no evidence-based option.
The disease is under-studied because it belongs to no organ-based specialty.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Median progression-free survival 6.
A milestone in how this cancer is treated.
Tumour-agnostic therapies: pembrolizumab or nivolumab for MSI-high or high tumour mutational burden, NTRK inhibitors, BRAF and MEK inhibitors, HER2-directed therapy.
Platinum-based doublet (carboplatin-paclitaxel or gemcitabine-cisplatin) for three cycles, then continuation or a switch to molecularly guided therapy where an actionable alteration is found (CUPISCO).
Best supportive care with early palliative care involvement.